Prostate Cancer

Pharmacokinetics of isotope-labeled antibody specific for PSA reported

Published in Medical Letter on the CDC and FDA, June 5th, 2005

Scientists present the pharmacokinetics and biodistribution of ¹¹¹In- and ¹⁷⁷Lu-labeled J591 antibody specific for prostate-specific membrane antigen in a recent issue of the Journal of Nuclear Medicine.

According to a study from the United States, "¹¹¹In-labeled antibodies and peptides have been routinely used as chemical and biologic surrogates for ⁹⁰Y-labeled therapeutic agents. However, recent studies have shown that there are significant differences in biodistribution between ¹¹¹In- and ⁹⁰Y-labeled agents. Yttrium and lutetium metals favor the +3 oxidation state, similar to indium, but there...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-06-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry